Core Insights - The report from Zhongkang Digital Technology Co., Ltd. indicates a significant shift in the pharmaceutical industry from "conceptual trials" to "practical implementation" of AI technologies [1] - Zhongkang Technology has established a comprehensive AI service ecosystem covering the entire industry chain, serving 1,685 clients, including 182 pharmaceutical companies and over 51 hospitals [1] Group 1: AI Implementation in Various Sectors - In marketing, Zhongkang Technology has launched the AI For Marketing Lab, marking a transition to a "trust-driven" marketing era, enhancing ROI visualization and maximization [2] - In the medical sector, the company supports over 510 hospitals with its self-developed "Zhuo Mu Niao Medical Model," which provides evidence-based decision-making tools for complex medical diagnoses [2] - The retail pharmacy sector has seen the deployment of AI systems in over 10,993 pharmacies, transforming operational logic and enhancing professional service capabilities [2] Group 2: Consumer Health Management - Zhongkang Technology has developed an AI system for comprehensive health management, utilizing a user base of over 3 million to provide personalized health interventions and risk warnings [3] - The company focuses on chronic disease and critical illness management, offering medication management and rehabilitation guidance while integrating humanistic care and policy interpretation [3][4] Group 3: Unique Data and Model Capabilities - Zhongkang Technology has transitioned from "data services" to "AI decision-making and intelligent services," creating a unique capability that combines data, models, scenarios, and ecosystems [5] - The company has developed specialized AI models, such as the Zhuo Mu Niao Medical Model, trained on extensive medical literature and knowledge graphs, ensuring high accuracy and relevance [5] - Zhongkang Technology possesses a high-quality data system that spans the entire industry chain, providing deep insights into market trends and patient behaviors [6] Group 4: Industry Challenges and Future Outlook - The pharmaceutical industry is entering a phase of "refined operations," where AI is becoming a fundamental capability rather than a mere vision, addressing challenges like normalized procurement and compliance pressures [7] - Zhongkang Technology aims to establish a "central operating system" for the health industry, integrating the entire value chain and covering all lifecycle application scenarios from prevention to management [7]

中康控股(02361.HK)发布公告，截至本公告日期，公司在AI大模型及AI智能体的商业化应用方面取得显 著进展，AI服务及产品覆盖营销、医疗健康、药店、消费者管理场景，触达"医、药、患"全范围的健康 产业合作网络。 ...

Core Insights - The company has made significant progress in the commercialization of AI large models and intelligent agents, covering various sectors including marketing, healthcare, pharmacies, and consumer management, thereby reaching a comprehensive health industry cooperation network [1] Group 1: Marketing - The company has launched the "AI Marketing Laboratory" and introduced the "Tiangong No.1 Commercial Intelligent Agent," providing "+AI" digital solutions to 182 pharmaceutical companies, enabling rapid response and efficient decision-making in a changing environment [1] Group 2: Healthcare - Utilizing its self-developed "Zhuo Mu Niao Medical Large Model," the company has introduced the intelligent agent "iMDT" for multidisciplinary joint consultations, serving 512 hospitals and empowering over 1,520 clinical doctors in complex medical diagnoses, significantly improving the decision quality of multidisciplinary teams (MDT) [1] Group 3: Pharmacy - The company has launched an intelligent agent for pharmacies, serving over 10,993 pharmacies, and established a matrix of five AI intelligent agents covering operational insights, products, diseases, members, and employees, as well as specialized AI for "individuals, families, diseases, and medications" to empower store operations [1] Group 4: Health Management - The company has created an AI intelligent agent matrix covering "individuals, families, diseases, and medications," accurately reaching over 3 million users, providing personalized health interventions and risk warnings, and constructing a comprehensive management system that includes prevention, screening, and intervention [1] Group 5: Business Transformation - The company has successfully transformed from a data technology service provider to an AI technology service provider, and will continue to optimize its capabilities in "data + models + scenarios + ecosystem" to become the preferred AI service provider in the health industry [2]

Core Insights - The company has made significant progress in the commercialization of AI large models and intelligent agents, covering various sectors in the health industry, including marketing, healthcare, pharmacies, and consumer management [1][2] Group 1: Marketing - The company has launched the "AI Marketing Laboratory" and introduced the "Tian Gong No. 1 Commercial Intelligent Agent," providing "+AI" digital solutions to 182 pharmaceutical companies, enabling rapid response and efficient decision-making in a changing environment [1] Group 2: Healthcare - Utilizing its self-developed "Zhuo Mu Niao Medical Large Model," the company has introduced the intelligent agent "iMDT" for multidisciplinary joint consultations, serving 512 hospitals and empowering over 1,520 clinical doctors in complex medical diagnoses, significantly improving the decision quality of multidisciplinary teams (MDT) [1] Group 3: Pharmacy - The company has launched an intelligent agent for pharmacies, serving over 10,993 pharmacies, and established a matrix of five AI intelligent agents covering operational insights, products, diseases, memberships, and employees, as well as specialized AI for "individuals, families, diseases, and medications" to enhance store operations [1] Group 4: Health Management - The company has created a matrix of AI intelligent agents covering "individuals, families, diseases, and medications," accurately reaching over 3 million users, providing personalized health interventions and risk warnings, and constructing a comprehensive management system that includes prevention, screening, and intervention [1] Group 5: Business Transformation - The company has successfully transformed from a data technology service provider to an AI technology service provider, continuously optimizing its capabilities in "data + models + scenarios + ecosystem" to become the preferred AI service provider in the health industry [2]

中康控股(02361)发布公告，公司董事会建议将公司的英文名称由"Sinohealth Holdings Limited"更改 为"Sinohealth Technology Holdings Limited"，而公司的中文双重外文名称由"中康控股有限公司"更改 为"中康科技控股有限公司"。 ...

格隆汇12月24日丨中康控股(02361.HK)发布公告，董事会建议将公司的英文名称由"Sinohealth HoldingsLimited"更改为"Sinohealth Technology Holdings Limited"，而公司的中文双重外文名称由"中康 控股有限公司"更改为"中康科技控股有限公司"。 ...

Core Insights - Zhongkang Holdings (02361.HK) has made significant progress in the commercialization of AI large models and intelligent agents, covering various sectors including marketing, healthcare, pharmacies, and consumer management [1] Marketing - The company has launched the "AI Marketing Laboratory" and introduced the "Tiangong No. 1 · Commercial Intelligent Agent," providing "+AI" digital solutions to 182 pharmaceutical companies, enabling rapid response and efficient decision-making in a changing environment [1] Healthcare - In the healthcare sector, the company has developed the "Zhuomuniao Medical Large Model" and launched the intelligent agent "iMDT" for multidisciplinary joint consultations, serving 512 hospitals and empowering over 1,520 clinical doctors to enhance the quality of decision-making in complex medical diagnoses [2] Pharmacies - In the pharmacy sector, the company has introduced an intelligent agent that has served over 10,993 pharmacies, utilizing comprehensive industry data to establish a matrix of five AI intelligent agents covering operational insights, products, diseases, members, and employees, as well as specialized AI for "individuals, families, diseases, and medications" to empower store operations [3] Consumer Management - In health management, the company has created a matrix of AI intelligent agents covering "individuals, families, diseases, and medications," accurately reaching over 3 million users, providing personalized health interventions and risk warnings, and constructing a comprehensive management system that includes prevention, screening, and intervention [4]

智通财经APP讯，中康控股(02361)发布公告，公司董事会建议将公司的英文名称由"Sinohealth Holdings Limited"更 改 为" Sinohealth Technology Holdings Limited"，而公司的中文双重外文名称由"中康控股有 限公司"更改为"中康科技控股有限公司"。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示不會就因本公告全部或任何部分內容而產生或因依賴該等內容 而引致的任何損失承擔任何責任。 Sinohealth Holdings Limited 中康控股有限公司 （於開曼群島註冊成立的有限公司） （股份代號：2361） 建議更改公司名稱 本公告由中康控股有限公司（「本公司」）根據香港聯合交易所有限公司證券上市規則（「上市 規則」）第13.51(1)條作出。 建議更改公司名稱 本 公 司 董 事（「董 事 」）會（「董事會 」）建 議 將 本 公 司 的 英 文 名 稱 由「Sinohealth Holdings Limited」更改為「Sinohealth Technology Holdings Limited」，而本公司的中文雙重外文名稱 由「中康控股有限公司」更改為「中康科技控股有限公司」（「建議更改公司名稱」）。 建議更改公司名稱的條件 建議更改公司名稱將須待以下條件達成後方可作實： – 1 – (i) 本公司股東（「股東」）於本公司股東特別大會（「股東特別大會」）通過批准建議更改公司 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示不會就因本公告全部或任何部分內容而產生或因依賴該等內容 而引致的任何損失承擔任何責任。 Sinohealth Holdings Limited 中康控股有限公司 茲提述中康控股有限公司（「本公司」，連同其附屬公司統稱「本集團」）日期為2022年6月28 日的招股章程（「招股章程」）「未來計劃及所得款項用途」一節及截至 2025年6月30日止六個 月的中期報告（「2025年中期報告」）「全球發售所得款項用途」一節。除非另有界定，否則本 公告所用詞彙與招股章程及2025年中期報告所界定者具有相同涵義。 （於開曼群島註冊成立的有限公司） 預期時間及所得款項用途變動 誠如2025年中期報告所披露，於2025年6月30日，於約339.6百萬港元的所得款項淨額總 額中，仍有約199.7百萬港元尚未動用。 基於下文「所得款項淨額用途變動的理由及裨益」一段所述的理由及裨益，經審慎考慮及詳 細評估本集團的營運及業務策略後，董事會已於2025年12月24日決議變更未動用所得款 項淨額的擬定用途，並更新悉數動用的 ...